Match each patient's clinical presentation of amenorrhea with the most appropriate targeted laboratory test or panel to establish the diagnosis.
- A 24-year-old phenotypic female presenting with primary amenorrhea, normal breast development, sparse pubic and axillary hair, and a surgically confirmed blind-ending vagina.Serum karyotype and testosterone level
- A 19-year-old female presenting with primary amenorrhea, lack of breast development, a normal uterus on pelvic ultrasound, and a lifelong inability to smell.Serum follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels
- A 28-year-old female presenting with secondary amenorrhea, recent-onset temporal balding, deepening of her voice, and rapidly progressive clitoromegaly over four months.Serum total testosterone and dehydroepiandrosterone sulfate (DHEA-S) levels
- A 34-year-old female presenting with a 6-month history of secondary amenorrhea, spontaneous bilateral galactorrhea, and a negative urine human chorionic gonadotropin test.Serum prolactin and thyroid-stimulating hormone (TSH) levels
Cevap
Presentation 1 matches with Karyotype/Testosterone; Presentation 2 matches with FSH/LH; Presentation 3 matches with Testosterone/DHEA-S; Presentation 4 matches with Prolactin/TSH.
The correct pairings directly address the unique pathophysiologic mechanisms of each amenorrhea presentation. CAIS requires genetic and hormonal confirmation to distinguish it from anatomic anomalies. Kallmann syndrome requires confirmation of central hypogonadism. Rapid virilization necessitates localizing the exact androgen source (ovary vs. adrenal). Galactorrhea workups must always include TSH due to the functional TRH-prolactin axis.
Adım Adım Çözüm
Anahtar Kavram
Targeted laboratory evaluation of amenorrhea relies on identifying specific clinical phenotypes (e.g., severe hyperandrogenism, galactorrhea, olfactory deficits, or anatomic anomalies) to select the most cost-effective and diagnostically accurate initial hormonal assays.